Assay Development. RMS shall be responsible for and shall conduct the Assay Development as set forth in the Project Plan, including the Clinical Validation of the RMS Product.
Assay Development. A Work Package may include the development of assays (including immunogenicity and potency/release assays), as will be described in the IPDP.
Assay Development. (a) The Screening Committee will allocate responsibilities between the parties for specific assay development tasks. In general, Neurocrine will develop the appropriate biochemical and/or cellular reagents for the assay and provide necessary quantities to Caliper for LabChip Assay development and screening. Initially, Caliper will direct work to adapt the assay into the LabChip format. Over time, the parties expect that Neurocrine will assume an increasing role in LabChip Assay development. The parties will arrange for Neurocrine scientists to train in LabChip Assay development at Caliper and/or for certain LabChip Assay development tools to be provided to Neurocrine. The Screening Committee will determine, or establish criteria for others to determine, when a LabChip Assay is ready for screening on Caliper's high throughput system.
Assay Development. Scopus Biopharma will contract with a Contract Research Organization (CRO) to develop and validate bioanalytical methods for rat, dog, and human plasma.
Assay Development. LabChip Assays for Amgen's Targets will be developed collaboratively by the parties or by Amgen independently, as determined by Amgen. In general, Amgen will [ * ]. Initially, Caliper will be primarily responsible for adapting the assay to the LabChip format. Over time, the parties expect that Amgen will [ * ].
Assay Development. For each Assay, BMS shall make a milestone payment to Exelixis of [ * ] after BMS' acceptance of such Assay pursuant to Section 3.5(a).
Assay Development. In the event that that Pharmacopeia shall conduct any additional assay validation as provided in Section 2.3, Organon shall pay to Pharmacopeia an amount equal to the number of FTE's to be utilized for such development multiplied by Pharmacopeia's FTE Rate for the agreed period of such development program. Solely for purposes of this Section 6.2, Pharmacopeia's "FTE Rate" shall be ***. In addition, in the event Organon agrees to the modification of an Assay, Organon shall reimburse Pharmacopeia for the cost of any reagents that Pharmacopeia needs to obtain to conduct its activities pursuant to this Section. Payments under this Section shall be made within thirty (30) days of receipt of an invoice.
Assay Development. Prometheus shall use Commercially Reasonable Efforts to develop Qualified Assays for [***] Analytes (or such lesser number as agreed to by BSP). This Assay development stage shall not be fully satisfied until Assays for [***] Analytes have been determined to be Qualified Assays, or until BSP agrees that a lesser number of Qualified Assays is sufficient; provided, however, when at least [***] of the Assays have been determined to be Qualified Assays (unless the JRC agrees to a lower percentage), each Qualified Assay shall proceed to the Cell Lysate Test, pursuant to Section 2.6.2(b). [***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Assay Development. It is anticipated that the Assay has been developed and validated by Organon prior to validation by Pharmacopeia. An Assay shall be considered validated if it meets the criteria set in Exhibit A. On a Target-by-Target basis, Pharmacopeia shall provide up to one (1) FTE month without additional charge to Organon for validation of the Assay for a particular Target. Insofar as the Assay requires additional development by Pharmacopeia or the use of any key reagents that have not been supplied by Organon, the Parties shall mutually agree on the payment of additional fees pursuant to Section 6.2. The Parties agree that all improvements and modifications directly relating to the Assay (collectively the "Assay Improvements") made solely by Pharmacopeia shall be owned by Pharmacopeia. All Assay Improvements that are made jointly by the Parties shall be jointly owned by the Parties. Each Party agrees to grant to the other Party license rights in its interest in Assay Improvements as provided herein.
Assay Development. Upon the selection by the RMC of a specific signal transduction target as a Validated Target, SUGEN will use reasonable efforts in accordance with the Research Plan to develop [ ] assays based upon such Validated Target (the "Target Assays"). It is understood that as of the Effective Date, SUGEN has already developed certain assays based on the [ ] target, which assays shall be deemed Target Assays if the [ ] target is determined to be a Validated Target. All such Target Assays will be optimized for efficient screening of the compounds to determine [ ] of compounds, in order to identify Active Compounds. During the Research Term, SUGEN shall continue to develop and improve the Target Assays. Allergan shall cooperate with SUGEN as reasonable in developing such Target Assays.
